Search

Displaying results 2611 - 2620 of 7602 in total
  1. Drug

    Resmetirom

    go.drugbank.com/drugs/DB12914
    ApprovedInvestigational

    On March 14, 2024, it was approved by the FDA as the first treatment of liver fibrosis due to noncirrhotic non-alcoholic steatohepatitis (NASH), which is a form of non-alcoholic fatty liver disease (NAFLD

  2. Drug

    Adrafinil

    go.drugbank.com/drugs/DB08925
    ApprovedWithdrawn

    It is also been used off-label to prevent fatigue or falling asleep for extended periods of time. Adrafinil does not currently have FDA approval and is thus unregulated in the United States.

    Categories: Psychostimulants, Agents Used for ADHD and Nootropics
  3. Drug

    Emapalumab

    go.drugbank.com/drugs/DB14724
    ApprovedInvestigational

    Emapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018. The approval of...

  4. Drug

    Crotalus atrox antivenin

    go.drugbank.com/drugs/DB13892
    Approved

    Each year it is estimated there are 45,000 snakebites in the US and 300,000 to 400,000 bites worldwide. About 8000 of these snakebites involve venomous snake species.

  5. Drug

    Levobupivacaine

    go.drugbank.com/drugs/DB01002
    ApprovedInvestigationalWithdrawn

    It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal … In general, the majority of potential adverse effects are predominantly associated with inappropriate administration methods that may cause systemic exposure and/or toxicity associated with overexposure

  6. Drug

    Orlistat

    go.drugbank.com/drugs/DB01083
    ApprovedInvestigational

    It was approved by the FDA for use in combination with a reduced-calorie diet in 1999. … In some individuals, diet and exercise are insufficient to maintain weight loss, and pharmacological or surgical intervention is required.

    Products: SOGRAS CAPSULA POR 120MG, ORLISTAT MK 120 MG CAPSULAS
  7. Drug

    Dicoumarol

    go.drugbank.com/drugs/DB00266
    Approved

    Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K.

    Categories: Vitamin K Antagonists
  8. Drug

    Vericiguat

    go.drugbank.com/drugs/DB15456
    ApprovedInvestigational

    [L31178] Vericiguat was approved by the FDA in January 2021 - developed by Merck under the brand name Verquvo - for use in certain patients with systolic heart failure. … to its structure have dramatically decreased its susceptibility to oxidative metabolism,[A227458] resulting in a relatively long half-life and allowing for once-daily dosing.

  9. Drug

    CX-052075

    go.drugbank.com/drugs/DB31655
    Approved

    [L53413,A274083] mNEXSPIKE was approved by the US FDA in June 2025 for use in patients who have been previously vaccinated with any COVID-19 vaccine and who are at a higher risk of severe outcomes from … approved COVID-19 mRNA vaccines, including the original Moderna COVID-19 vaccine ([elasomeran]), CX-052075 encodes only the immunodominant regions (NTD and RBD) of the SARS-CoV-2 spike protein, allowing for

  10. Drug

    AZD3409

    go.drugbank.com/drugs/DB04893
    Experimental

    AZD3409 is a farnesyl-transferase inhibitor (FAR) indicated for the treatment of solid tumors. Phase I trials were initiated January 2003, and were ongoing as of February 2004.